$DNTH News

Dianthus Therapeutics: A Financed Autoimmune Platform With More Than One Way To Win

Wedbush Maintains Outperform on Dianthus Therapeutics, Raises Price Target to $105

Dianthus Therapeutics Q1 EPS $(0.85) Beats $(1.07) Estimate, Sales $463.000K Beat $354.214K Estimate

Wolfe Research Initiates Coverage On Dianthus Therapeutics with Outperform Rating, Announces Price Target of $98

Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Dianthus Therapeutics CFO Sells $9.5 Million in Stock

How Investors May Respond To Dianthus Therapeutics (DNTH) Early “GO” Decision And FDA Backing For Claseprubart

Strength Seen in Dianthus Therapeutics, Inc. (DNTH): Can Its 5.6% Jump Turn into More Strength?

Wells Fargo Initiates Coverage On Dianthus Therapeutics with Overweight Rating, Announces Price Target of $135

Wedbush Keeps Outperform on Dianthus Therapeutics, Inc. (DNTH), Highlights Potential of Claseprubart in CIDP

Dianthus Therapeutics Hits Early “Go” in CAPTIVATE Phase 3 CIDP Trial, Drops 600 mg Arm

Dianthus Therapeutics (DNTH) Is Up 30.8% After Upsized Raise And Early Phase 3 “Go” Decision

Dianthus Therapeutics, Inc. Announces Closing of its Upsized $719 Million Underwritten Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares

Wedbush Maintains Outperform on Dianthus Therapeutics, Raises Price Target to $103

Dianthus Therapeutics, Inc. Announces Pricing of Upsized $625 Million Underwritten Public Offering

Reported Earlier, Dianthus Therapeutics Prices Upsized $625M Public Offering Of 7,313,582 Common Shares At $81 Per Share To Advance Autoimmune Disease Pipeline

Reported Earlier, Dianthus Therapeutics Prices Upsized $625M Public Offering Of 7,313,582 Common Shares At $81 Per Share To Advance Autoimmune Disease Pipeline

Dianthus Therapeutics shares are trading higher after multiple analyst firms raised their respective price targets on the stock.

Dianthus Therapeutics: Go Decision For CIDP Program Warrants Continued Buy Rating

Guggenheim Reiterates Buy Rating for Dianthus Therapeutics (DNTH)